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INTRODUCTION
The liver is a common site of metastasis from many primary
sites, particularly the lung, breast, and the gastrointestinal
tract, and hepatocellular carcinoma (HCC) may show a variety
of histologic patterns (1). The pathologic diagnosis of HCC
may be difficult using routine histologic stains, particularly
when judgement must be rendered based on a small biopsy
specimen. Immunohistochemistry has been applied extensively
to hepatic neoplasms for the differential diagnosis of HCC,
cholangiocarcinoma, and metastatic carcinoma. The marker
most commonly used is alpha-fetoprotein (AFP) (2), but unfor-
tunately, its sensitivity is low in tumor tissue. Only 25-45%
of HCC cases are positive for AFP by immunohistochem-
istry, and even then, its expression is often patchy and weak
(1, 3, 4). Other markers, including polyclonal carcinoembryon-
ic antigen (pCEA), ferritin, albumin, fibrinogen, and alpha-
1-antitrypsin, are also used (1, 5, 6, 8).
It has been reported that normal adult liver cells contain
cytokeratin (CK) 8 and CK18, whereas bile duct epithelial
cells contain CK7, 8, 18, and 19, and metastatic carcinomas
express sets of CKs that are derived from their primary sites
of origin. Therefore, an immunostaining panel of CK7, CK19,
and CK20 is helpful for the differential diagnosis of HCC;
however, these CK expression sets often overlap. Moreover, it
has been found that the expressions of CKs may change when
malignancy develops, and additionally, 5-20% of cases of
HCCs cannot be diagnosed by CK immunostaining (9-12). 
In 1993, Wennerberg et al. reported the development of a
new monoclonal antibody named hepatocyte paraffin 1 (Hep),
which reacts with paraffin-embedded normal and neoplastic
liver tissue (13). A number of subsequent studies then con-
firmed Hep as a relatively specific marker for HCC, though
some gastric adenocarcinomas, neuroendocrine carcinomas, and
cholangiocarcinomas were also found to be positive for Hep
(14-16). Because previous studies have not examined large
numbers of cases of each tumor, it is uncertain how Hep expres-
sion correlates to the histologic patterns of HCC or non-HCC.
In addition, Hep expressions in normal adult or fetal tissues
other than liver have not been extensively studied. In this st-
udy, we evaluated the expression of Hep in 75 HCCs, and in
407 non-HCCs. Because Hep was expressed in the intestinal
metaplasia of the stomach and mucosal columnar cells of small
intestine, but not in colorectal mucosa, by the test procedure
using human control slide for immunohistochemistry (Super-
biochips Laboratories, Seoul, Korea), we evaluated Hep expres-
sions in colonic type and small intestinal type of intestinal
metaplasia. For analysis of the correlation between the degree
of cell differentiation and Hep-positivity, the digestive organs
of the fetus of various gestational ages were included in this
study.
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Hepatocyte Expressions in Hepatocellular Carcinomas, Gastrointestinal
Neoplasms, and Non-neoplastic Gastrointestinal Mucosa: its Role as
a Diagnostic Marker
We performed immunohistochemical staining against Hepatocyte (Hep) and CD10
antibodies in 75 hepatocellular carcinoma (HCC), 50 cholangiocarcinomas, 49 col-
orectal adenocarcinomas, and 308 gastric adenocarcinomas by tissue array method.
We also evaluated the various non-neoplastic adult tissues and fetal digestive organs.
Hep was expressed in 80% of HCCs, and HCCs without Hep expression were more
likely to have a higher Edmondson & Steiner grade than HCCs with Hep expression
(p=0.004). In non-HCCs, 16% of cholangiocarcinomas, 8.2% of colorectal carcino-
mas, and 44.2% of gastric carcinomas expressed Hep. Gastric carcinomas with Hep
expression were significantly associated with early gastric carcinomas (p<0.001).
In non-neoplastic tissues, Hep was found expressed in normal hepatocytes, small
intestinal mucosa, and intestinal metaplasia of the stomach. Fetal hepatocytes expr-
essed Hep after 19 weeks of gestation. CD10 was detected in 46.7% (35/75) of
HCCs, and canalicular staining pattern was predominant in HCCs. In conclusion, the
expression of Hep and CD10 may help to distinguish HCCs from non-HCCs.
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MATERIALS AND METHODS
Cases
Seventy-five cases of primary HCCs from the files of the
Department of Pathology, Seoul National University Hos-
pital, Seoul, Korea were examined in this study. To evaluate
immunoreactivity in non-HCCs, we studied 50 primary chol-
angiocarcinomas, 49 primary colorectal adenocarcinomas, and
308 primary gastric adenocarcinomas. All of these tumors had
been surgically resected, fixed in 10% neutral formalin and
embedded in paraffin. Glass slides were reviewed for histologic
classification and differentiation using the Edmondson & Stein-
er nuclear grading system (17) and histological pattern catego-
rization (18) for HCCs, and the WHO classification (19, 20)
for non-HCCs.
Non-neoplastic adult tissues were obtained from; 15 cases
of intestinal metaplasia of the stomach (resected specimens
from gastric adenocarcinomas), 5 duodenum samples (resected
specimens from gastric adenocarcinomas), and 4 colorectum
samples (resected specimens from colorectal adenocarcino-
mas). In addition, digestive organs, including the tongue,
liver, esophagus, stomach, small intestine, and colorectum, of
variable gestational ages (i.e., of 15, 16, 19-22, 24, 28, and
30 weeks of gestation) were selected.
Tissue-Array Methods
All of the above tissues, except 17 cases of HCCs which
were stained using whole section slides, were evaluated using
the tissue-array methods. Core tissue biopsies (2 mm in dia-
meter of tumor and fetal tissue, and 4 mm in diameter for non-
neoplastic tissues) were taken from individual paraffin-embed-
ded tissues (donor blocks) and were arranged in a new recip-
ient paraffin block (tissue array block) using a trephine appa-
ratus (Superbiochips Laboratories, Seoul, Korea) (21). Each
tissue array block contained up to sixty cases, and the study
involved a total of 11 blocks of tissue-array blocks. An adequate
case was defined as a tumor occupying more than 10% of the
core area.
Immunohistochemistry
Four- m thick sections were cut from whole tissue blocks
or tissue-array blocks, deparaffinized and dehydrated. Immuno-
histochemical stainings against Hep (1:100, DAKO Corpora-
tion, Glostrup, Denmark) were performed using a strepta-
vidin peroxidase based procedure after an antigen retrieval
using microwaves. The immunolabeling pattern of each case
was scored as positive (strong labeling), weakly positive (faint
staining), or negative (absence of staining), and the extent of
immunolabeling were scored as diffusely positive (≥90%),
focally positive (5-89%), or negative (<5%). For the statistical
analysis, the results of immunostaining were considered pos-
itive if 5% or more of the cells were positive (strong labeling).
We were able to perform the test procedure using human
control slide for immunohistochemistry (Superbiochips Lab-
oratories). Hep was found to be expressed only in hepatocytes,
HCCs, the intestinal metaplasia of the stomach, and in the
mucosal columnar cells of small intestine. Other neoplastic
or non-neoplastic tissues, including the skin, breast, pancreas,
lymph node, stomach, lung, salivary gland, bile duct, spleen,
gallbladder, colorectum, kidney, prostate, seminal vesicle, testis,
uterus, placenta, adrenal, thyroid, brain and their various tu-
mors, were almost all negative for Hep reactivity.
In addition, immunohistochemical stainings against CD10
(1:80, Novocastra Laboratories Ltd., Newcastle upon Tyne,
U.K.) were performed in HCCs and non-HCCs, as described
above. The results of immunostaining were considered to be
positive, if ≥5% of the cells were positive and they could
be categorized as canalicular, non-canalicular (membranous)
or cytoplasmic in pattern (22).
HID-AB2.5 Staining
High iron diamine and alcian blue (pH 2.5) (HID-AB2.5)
staining was used, to stain sulphated (brown) and acidic non-
sulphated (blue) mucosubstances simultaneously, in 15 cases
of intestinal metaplasia of the stomach. Intestinal metaplasia
was classified, as previously described (23), as follows: type I,
mature absorptive cells and goblet cells, the latter secreting
sialomucins; type II, few or absent absorptive cells, presence
of columnar ‘‘intermediate’’ cells in various stages of differen-
tiation secreting neutral and acid sialomucins and goblet cells
secreting sialomucins or, occasionally, sulfomucins, or both;
and type III, columnar ‘‘intermediate’’ cells secreting predom-
inantly sulfomucins and goblet cells secreting sialomucins or
sulfomucins, or both.
Statistical Analyses
Either the chi-square test or Fisher’s exact test (2-sided)
was used to determine the correlation between the histologic
grade of HCCs or non-HCCs and Hep expression status.
Results were considered as statistically significant at p values
of less than <0.05. All statistical analyses were conducted using
the SPSS 11.0 (SPSS, Chicago, IL).
RESULTS
Hepatocyte Expressions in HCCs and Other
Carcinomas
Of the 75 cases of HCCs, 60 were positive for Hep (80%)
(Table 1). The Hep staining pattern is distinctly granular and
diffusely cytoplasmic (Fig. 1). Hep expression was found in
16% (8/50) of cholangiocarcinomas, in 8.2% (4/49) of colo-844 H.S. Lee, W.H. Kim, G.H. Kang
rectal adenocarcinomas, and in 44.2% (136/308) of gastric
adenocarcinomas. Hep staining in some of the HCCs and non-
HCCs was restricted to focal areas, and the density of such
staining varied from cell to cell. A diffuse staining pattern was
more frequently seen in Hep-positive HCCs (36/60, 60%)
than in Hep-positive non-HCCs (40/148, 27%), of which
difference was statistically significant (p<0.001). In this series,
Hep staining had a sensitivity of 80.0% and specificity of
63.6% in detecting HCCs.
Table 2 shows the correlation between Hep expression and
the histologic grade of HCCs or non-HCCs. HCCs without
Hep expression were more likely to have higher Edmondson
& Steiner grades than HCCs with Hep expression (p=0.004).
All 4 cases of HCCs with compact or scirrhous pattern were
negative for Hep. In non-HCCs, Hep expressions was more
frequently found in well-differentiated adenocarcinomas rather
than in poorly differentiated type, and this was statistically
significant in cholangiocarcinomas (p=0.035) and gastric ade-
nocarcinomas (p<0.001). Signet ring cell carcinomas and mu-
cinous carcinomas of the stomach frequently showed Hep
expression, and Hep expression was more frequently seen in
early gastric carcinomas than in advanced carcinomas (p<
0.001). Histologic classification of colorectal adenocarcinoma
was not associated with Hep expression status (p=0.155).
Hepatocyte Expressions in Non-Neoplastic Human 
Tissues
As a result of a human control slide in the test procedure,
normal hepatocytes, mucosal columnar cells of the small intes-
tine and intestinal metaplasia of stomach were found to express
Hep. Therefore, we constructed a tissue-array slide, consist-
ing of 15 cases of intestinal metaplasia of the stomach, 5 of
the duodenum and 4 of the colorectum, and performed HID-
AB2.5 staining and immunohistochemical staining against
Hep. All 5 duodenal mucosa were positive for Hep, while the
4 colorectal samples were negative. HID-AB2.5 staining,
showed that 15 cases of intestinal metaplasia were classifiable
as; 7 cases of intestinal metaplasia type I, 5 cases of type II, and
3 cases of type III. All cases of type I and type III showed Hep
expression, but only 2 cases out of 5 type II showed Hep expres-
sion. Hep expression in types II and III was restricted to focal
areas (Fig. 2A-J).
Fetal hepatocytes with 15 and or 16 weeks of gestation were
negative for Hep, while only 5% of hepatocytes were positive
*HCC, hepatocellular carcioma; 
� adenoca., adenocarcinoma.
*HCCs
Non-HCCs
Cholangio-
carcinoma
Colorectal
� adenoca.
Gastric
adenoca.
Positive
Diffuse (≥90%) 36 3 1 36
Focal (5-89%) 24 5 3 100
Total  60 (80%) 8 (16%) 4 (8.2%) 136 (44.2%)
Negative (<5%) 15 (20%) 42 (84%) 45 (91.8%) 172 (54.8%)
Total cases 75 (100%) 50 (100%) 49 (100%) 308 (100%)
Table 1. Hepatocyte expressions in HCCs and non-HCCs
Fig. 1. The immunostaining of Hep was found in HCCs (A, ×200), early gastric carcinoma (B, ×200), cholangiocarcinoma (C, ×200), and
colonic adenocarcinoma (D, ×200). A canalicular staining pattern of CD10 is only found in HCCs (E, ×200) and a non-canalicular mem-
branous staining pattern of CD10 is seen in colonic adenocarcinoma (F, ×200).
A
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C
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Fig. 2. According to the staining results of human control slide, hepatocytes, HCC and small intestinal mucosa are positive for Hep (A). Hep
is positive in normal hepatocytes (B, ×200) and duodenum (C, ×200), but negative in colon (D, ×200). HID-AB2.5 histochemical stains
divide gastric mucosa with intestinal metaplasia into type I (E, ×200), type II (F, ×200), or type III (G, ×200). Type I is positive for Hep (H,
×200), but type II (I, ×200) and type III (J, ×200) are focal positive. Only 5% of hepatocytes are positive in fetus at 19 weeks of gestation
(K, ×200), and diffusely positive in fetus at 20 weeks of gestation (L, ×200). Fetal small intestine at 20 weeks of gestation show diffuse Hep
expression (M, ×200).
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in the fetus at 19 weeks of gestation, and were diffusely pos-
itive in the fetus with 20, 21, 22, 24, 28 and 30 weeks of
gestation. No staining of the bile ducts or other nonparenchy-
mal cells in the fetus was observed. Fetal mucosa of the small
intestine with 20, 21, 24, 28 and 30 weeks of gestation was
also observed expressing Hep. Another fetal digestive organs,
such as the tongue, esophagus, stomach and colon with at any
gestational age, did not show Hep expression (Fig. 2K-M).
CD10 Expressions in HCCs and Non-HCCs
CD10 was detected in 46.7% (35/75) of HCCs, 36% (18/
50) of cholangiocarcinomas, 40.8% (20/49) of colorectal ade-
nocarcinomas, and in 14% (42/300) of gastric adenocarcino-
mas (Fig. 1, Table 3). The staining pattern was either canalic-
ular, non-canalicular (membranous), or cytoplasmic (22). The
canalicular staining pattern was predominated in HCCs (22
out of 38 CD10-positive HCCs), but this pattern was not
found in non-HCCs. The canalicular staining was only seen
in trabecular, and mixed trabecular and pseudoglandular pat-
terns of HCCs, and not in the compact, scirrhous or pseudog-
landular patterns (data not shown).
DISCUSSION
Hep is a monoclonal antibody that reacts with a hepatocyte-
specific epitope resistant to formalin fixation and tissue pro-
cessing. The granular intracytoplasmic staining pattern sug-
gests organelle localization, possibly mitochondrial, but the
target antigen has been remains unknown (13). Unlike AFP,
the sensitivity of Hep in HCCs is relatively high. Hep sensi-
tivity in the previously reported and present study was 80%
or more (13, 14, 16, 24-26). AFP and Hep expressions in
HCCs are associated with histologic grade, and poorly dif-
ferentiated HCCs are more likely to be AFP positive (16).
Well differentiated tumors are also more likely to be Hep
positive. Immunostaining with another diagnostic markers,
such as a set of CKs, could result in more accurate diagnoses.
However, CK expressions may change when malignancy devel-
ops, and the CK staining patterns of gastric adenocarcinomas
are very heterogenous (12). Therefore, immunostaining with
Hep and AFP in combination with a set of CKs in HCCs
would increase diagnostic sensitivity and specificity. 
In their original report, Wennerberg et al. found that nine
of 205 cases of non-HCCs (5%) were Hep positive (13). All
nine of these cases were from the gastrointestinal tract, and
3 of 10 gastric adenocarcinomas (all were poorly differentiated,
signet ring, or mixed intestinal/signet ring) showed Hep
expression. A number of subsequent studies revealed that 30-
45% of gastric adenocarcinomas were positive for Hep, where-
as only 7-15% of cholangiocarcinomas and 0-5% of colorectal
adenocarcinomas showed Hep expression (14, 16, 24). Because
HCCs
Non-HCCs
Cholangiocarcinoma
Colorectal 
adenocarcinoma
Gastric 
adenocarcinoma
Canalicular 21/75 (28%) 0/50 (0%) 0/49 (0%) 0/300 (0%)
Non-canalicular 10/75 (13.3%) 13/50 (26%) 15/49 (30.6%) 32/300 (10.7%)
Cytoplasm 4/75 (5.4%) 5/50 (10%) 5/49 (10.2%) 10/300 (3.3%)
Total positive 35/75 (46.7%) 18/50 (36%) 20/49 (40.8%) 42/300 (14%)
Table 3. CD10 expressions in HCCs and non-HCCs
Tumor p value Positive
cases
No. of
cases
Hepatocellular carcinoma
Edmondson-Steiner grade 0.004
I 9 9 (100%)
II 29 27 (93.1%)
III 20 15 (75%)
IV 17 9 (52.9%)
Architectural patterns 0.001
Trabecular 57 46 (80.7%)
Pseudoglandular 1 1 (100%)
Mixed 13 13 (100%)
Compact 3 0 (0%)
Scirrhous 1 0 (0%)
Cholangiocarcinoma 0.035
(differentiation)
Well differentiated 6 3 (50%)
Moderate differentiated 27 2 (7.4%)
Poor differentiated 17 3 (17.6%)
Gastric adenocarcinoma
WHO classification <0.001
Well differentiated 29 20 (69%)
Moderate differentiated 82 29 (35.4%)
Poor differentiated 133 47 (35.3%)
Signet ring cell carcinoma 15 12 (80%)
Mucinous carcinoma 49 28 (57.1%)
Tumor progression <0.001
Early gastric carcinoma 92 58 (63%)
Advanced gastric  216 78 (36.1%)
carcinoma
Colorectal adenocarcinoma
Well differentiated 2 1 (50%) 0.155
Moderate differentiated 41 3 (7.3%)
Poor differentiated 5 0 (0%)
Mucinous carcinoma 1 0 (0%)
Table 2. The correlation between Hepatocyte expression and
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non-HCCs in our study mainly consisted of gastric adenocar-
cinomas, Hep specificity in the present study (63.6%) was
lower than that previously reported (about 94%) (13, 14, 16,
24-26). However, the distinct histopathologic features of Hep-
positive gastric adenocarcinomas may be helpful in differen-
tial diagnosis. Gastric adenocarcinomas with Hep expression
showed a tendency of having well differentiated tubular, signet
ring and mucinous histologic types, and were associated with
early gastric carcinomas, which had exceptionally rare liver
metastasis. Additionally, Hep staining in gastric carcinoma
was more frequently restricted to focal areas than in HCCs.
However, well differentiated HCCs more frequently showed
Hep expression, tumor cells of HCCs did not produce mucin,
and diffuse staining was more frequent than in non-HCCs. 
In this study, fetal hepatocytes at 15 and 16 weeks of ges-
tation did not show Hep expression, while fetal hepatocytes
showed Hep expression after 19 weeks of gestation. Hep ex-
pression in normal hepatocytes was more intense and diffuse
than in HCCs, and Hep positivity was significantly associated
with the differentiation of HCCs. These results suggest that
Hep immunoreactivity is a reflection of the degree of hepato-
cyte differentiation. Fasano et al. (27) reported that the staining
pattern of Hep in hepatoblastomas was more focal in distri-
bution, more variable and less intense than in the surround-
ing normal liver, and that Hep staining was generally less
intense in embryonal- than in fetal-type hepatoblastoma. They
also suggest the existence of a correlation between Hep-pos-
itivity and the degree of hepatocyte differentiation.
Intestinal metaplasia appears to take two major forms, com-
plete and incomplete, based on similarities in structure and
function to the normal mucosa of the small intestine and of
the colon (28-30). In the complete type (type I) of intestinal
metaplasia, the lesion most closely resembles the small intes-
tine and reveals numerous columnar absorptive cells. In con-
trast, the incomplete type (types II and III) consists of a mix-
ture of gastric foveolar and colonic type goblet cells. According
to the results of the human control slide (Superbiochips Lab-
oratories, Seoul, Korea), small intestinal mucosa and intestinal
metaplasia of the stomach were positive for Hep, and showed
a distinct granular cytoplasmic expression pattern, but colorec-
tal mucosa was negative for Hep. Therefore, it has been sug-
gested that Hep expression may be restricted to intestinal
metaplasia of type I. By using HID-AB2.5 staining, 15 intesti-
nal metaplasia were divided into 7 of the complete type and
8 of the incomplete type, but this typing was not entirely con-
sistent with the Hep expression status. This was perhaps be-
cause HID-AB2.5 staining could not strictly categorize the
types of intestinal metaplasia, and because this typing of in-
testinal metaplasia had a spectrum with considerable hetero-
geneity (28, 31).
In this study, we investigated using the tissue array method,
and found that this method enabled us to analyze a large num-
ber of HCCs and non-HCCs, especially gastric adenocarcino-
mas. Accordingly, we could evaluate the correlation between
Hep expression status and the histopathologic patterns of
HCCs or non-HCCs statistically. The potential limitations of
this method are mainly associated with the acquisition of infor-
mation from only a tiny area in each tumor. Because intratu-
moral heterogeneity of the Hep antigen expression has been
reported, and was also found observed in this study, it might
be that the Hep expression status in our study was under or
overestimated. In order to address the influence of tumor het-
erogeneity, multiple replicate tissue array blocks were const-
ructed, both by ourselves and by other researchers (18, 32, 33).
In all such research, the results from each replica array were
almost identical, statistically meaningful. In this study, the
positivity of Hep in HCCs using whole section slides was
82.4% (14/17) and positivity using tissue-array slides was
79.3% (46/58), which was not statistically significant (data
not shown).
CD10 is a 100-kD cell surface metalloproteinase, which
was originally identified on tumor cells of acute lymphoblastic
leukemia, and was thus named as common acute lymphoblas-
tic leukemia antigen (CALLA) (34). It was shown recently that
CD10 is expressed in both normal and neoplastic liver tissue,
where it exhibits a canalicular distribution pattern. Thus,
CD10 may be a serve as an useful additional marker for dif-
ferentiating HCCs and non-HCCs (22, 35, 36). In the present
study, only HCCs showed a canalicular CD10 expression pat-
tern, which also suggests that CD10 may be helpful for in the
differential diagnosis of HCCs from non-HCCs.
In summary, Hep expression was found to be highly sensitive
in detecting HCCs. However, about 40% of gastric adenocar-
cinomas also showed Hep expression, and the specificity of
Hep expression was low at detecting HCCs. Because gastric
adenocarcinomas with Hep expression had somewhat different
histopathologic features from HCCs with Hep expression, Hep
expression status could be helpful for the diagnosis of HCC,
especially by using a panel approach in combination with
AFP and CKs. In non-neoplastic tissues other than liver, small
intestinal mucosa and intestinal metaplasia also expressed
Hep with a distinct granular cytoplasmic staining.
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